Correction: Kwok et al. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers 2021, 13, 4681
- There was an error in the original publication. Page 3. “Monoallelic TP53 aberrations exert a more detrimental prognostic impact, compared to biallelic alterations.” This is incorrect. It should read: “Monoallelic TP53 alterations exert a less detrimental prognostic impact, compared to biallelic alterations.”
- There was an error in the original publication. Page 13. “In fact, among our recently reported cohort of 20 spontaneously regressing CLL cases, three harbored TP53 mutations [2].” Reference [2] was erroneously cited. The correct reference here should be reference [1]. This sentence should read: “In fact, among our recently reported cohort of 20 spontaneously regressing CLL cases, three harbored TP53 mutations [1].”
- There was an error in the original publication. Page 14. “in combination with existing immunomodulatory agents such as the PD-1/PD-L1 inhibitors lenalidomide and ibrutinib” This sentence should read in “in combination with existing immunomodulatory agents such as PD-1/PD-L1 inhibitors, lenalidomide and ibrutinib.”
- In the original publication, there was a mistake in Table 1: “Döhner” was misspelt as “Doner”. The corrected Table 1 appears below.
Reference
- Kwok, M.; Agathanggelou, A.; Davies, N.; Stankovic, T. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers 2021, 13, 4681. [Google Scholar] [CrossRef]
Gene | Mutation Frequency | Deletion Frequency | Number of Patients Analyzed | Reference |
---|---|---|---|---|
ATM | ND | 18% | 325 | Döhner et al., 2000 [17] |
32% | 4% | 50 | Stankovic et al., 2002 [13] | |
12% | 3% | 155 | Austen et al., 2005 [14] | |
ND | 22% | 330 | Malcikova et al., 2009 [15] | |
14.7% | 30% | 224 | Skowronska et al., 2012 [19] | |
8% | 15% | 160 | Landau et al., 2013 [25] | |
15% | 22% | 538 | Landau et al., 2015 [26] | |
TP53 | ND | 7% | 325 | Döhner et al., 2000 [17] |
12% | 6% | 50 | Stankovic et al., 2002 [13] | |
4% | ND | 155 | Austen et al., 2005 [14] | |
5% | 11% | 400 | Malcikova et al., 2009 [15] | |
8.5% | 5% | 328 | Zenz et al., 2010 [16] | |
7.6% | 6% | 529 | Gonzalez et al., 2011 [27] | |
15% | ND | 309 | Rossi et al., 2014 [28] | |
11.5% | 7% | 635 | Stilgenbauer et al., 2014 [29] | |
13% | 13% | 160 | Landau et al., 2013 [25] | |
7% | 6.3% | 538 | Landau et al., 2015 [26] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kwok, M.; Agathanggelou, A.; Davies, N.; Stankovic, T. Correction: Kwok et al. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers 2021, 13, 4681. Cancers 2022, 14, 321. https://doi.org/10.3390/cancers14020321
Kwok M, Agathanggelou A, Davies N, Stankovic T. Correction: Kwok et al. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers 2021, 13, 4681. Cancers. 2022; 14(2):321. https://doi.org/10.3390/cancers14020321
Chicago/Turabian StyleKwok, Marwan, Angelo Agathanggelou, Nicholas Davies, and Tatjana Stankovic. 2022. "Correction: Kwok et al. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers 2021, 13, 4681" Cancers 14, no. 2: 321. https://doi.org/10.3390/cancers14020321
APA StyleKwok, M., Agathanggelou, A., Davies, N., & Stankovic, T. (2022). Correction: Kwok et al. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers 2021, 13, 4681. Cancers, 14(2), 321. https://doi.org/10.3390/cancers14020321